Updated on 2022/04/13

写真a

 
IWANAMI Shoya
 
Organization
Graduate School of Science Assistant Professor
Graduate School
Graduate School of Science
Undergraduate School
School of Science Department of Biological Science
Title
Assistant Professor
Contact information
メールアドレス
External link

Degree 1

  1. 博士(理学) ( 2020.9   九州大学 ) 

Research Areas 2

  1. Natural Science / Biophysics, chemical physics and soft matter physics  / Mathematical Biology

  2. Natural Science / Applied mathematics and statistics

Current Research Project and SDGs 1

  1. 数理科学による感染症の理解

Research History 5

  1. Nagoya University   Graduate School of Science   Assistant Professor

    2022.4

      More details

    Country:Japan

    researchmap

  2. Nagoya University   Division of Biological Science, Graduate School of Science   Assistant Professor

    2021.4 - 2022.3

      More details

    Country:Japan

    researchmap

  3. Kyushu University   Department of Biology, Faculty of Science   Postdoctoral fellow   Research Assistant Professor

    2020.12 - 2021.3

      More details

    Country:Japan

    researchmap

  4. Kyushu University   Department of Biology, Faculty of Science   Postdoctoral fellow

    2020.10 - 2020.11

      More details

    Country:Japan

    researchmap

  5. Kyushu University   Graduate School of Systems Life Sciences   JSPS Research Fellow DC2

    2019.4 - 2020.9

      More details

    Country:Japan

    researchmap

Education 1

  1. Kyushu University   Graduate School of Systems Life Sciences

    2016.4 - 2020.9

      More details

    Country: Japan

    researchmap

 

Papers 17

  1. Factors Associated with COVID-19 Vaccine Booster Hesitancy: A Retrospective Cohort Study, Fukushima Vaccination Community Survey

    Makoto Yoshida, Yurie Kobashi, Takeshi Kawamura, Yuzo Shimazu, Yoshitaka Nishikawa, Fumiya Omata, Tianchen Zhao, Chika Yamamoto, Yudai Kaneko, Aya Nakayama, Morihito Takita, Naomi Ito, Moe Kawashima, Sota Sugiura, Kenji Shibuya, Shingo Iwami, Kwangsu Kim, Shoya Iwanami, Tatsuhiko Kodama, Masaharu Tsubokura

    Vaccines   Vol. 10 ( 4 ) page: 515 - 515   2022.3

     More details

    Publishing type:Research paper (scientific journal)   Publisher:MDPI AG  

    This was a retrospective cohort study, which aimed to investigate the factors associated with hesitancy to receive a third dose of a coronavirus disease 2019 (COVID-19) vaccine. A paper-based questionnaire survey was administered to all participants. This study included participants who provided answers in the questionnaire about whether they had an intent to receive a third dose of a vaccine. Data on sex, age, area of residence, adverse reactions after the second vaccination, whether the third vaccination was desired, and reasons to accept or hesitate over the booster vaccination were retrieved. Among the 2439 participants, with a mean (±SD) age of 52.6 ± 18.9 years, and a median IgG-S antibody titer of 324.9 (AU/mL), 97.9% of participants indicated their intent to accept a third vaccination dose. The logistic regression revealed that participants of a younger age (OR = 0.98; 95% CI: 0.96–1.00) and with a higher antibody level (OR = 2.52; 95% CI: 1.27–4.99) were positively associated with hesitancy over the third vaccine. The efficacy of the COVID-19 vaccine and concerns about adverse reactions had a significant impact on behavior regarding the third vaccination. A rapid increase in the booster dose rate is needed to control the pandemic, and specific approaches should be taken with these groups that are likely to hesitate over the third vaccine, subsequently increasing booster contact rate.

    DOI: 10.3390/vaccines10040515

    researchmap

  2. Designing isolation guidelines for COVID-19 patients utilizing rapid antigen tests: a simulation study using viral dynamics models.

    Jeong YD, Ejima K, Kim KS, Joohyeon W, Iwanami S, Fujita Y, Jung IH, Shibuya K, Iwami S, Bento AI, Ajelli M

    medRxiv : the preprint server for health sciences     2022.1

     More details

    Language:English  

    DOI: 10.1101/2022.01.24.22269769

    PubMed

  3. Detection of significant antiviral drug effects on COVID-19 using viral load and PCR-positive rate in randomized controlled trials

    Marwa AKAO, Joohyeon WOO, Shingo IWAMI, Shoya IWANAMI

    Translational and Regulatory Sciences   Vol. 3 ( 3 ) page: 85 - 88   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMED iD3 Catalyst Unit  

    <p>To evaluate the effects of antiviral drugs against coronavirus disease (COVID-19), we calculated the sample size needed to detect significant differences in daily viral load in randomized controlled trials. While calculating sample sizes, simulated viral loads that mimicked longitudinal clinical data were used. The sample size computed from the viral load was the smallest 2 to 4 days after trial participation, while the smallest sample size computed from the positive rate was 4 to 7 days after clinical trial participation.</p>

    DOI: 10.33611/trs.2021-025

    CiNii Research

    researchmap

  4. Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection

    Kwang Su Kim, Shoya Iwanami, Takafumi Oda, Yasuhisa Fujita, Keiji Kuba, Taiga Miyazaki, Keisuke Ejima, Shingo Iwami

    Life Science Alliance   Vol. 4 ( 10 )   2021.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.26508/LSA.202101049

    Web of Science

    Scopus

    PubMed

    researchmap

  5. Revisiting the guidelines for ending isolation for COVID-19 patients

    Yong Dam Jeong, Keisuke Ejima, Kwang Su Kim, Shoya Iwanami, Ana I Bento, Yasuhisa Fujita, Il Hyo Jung, Kazuyuki Aihara, Koichi Watashi, Taiga Miyazaki, Takaji Wakita, Shingo Iwami, Marco Ajelli

    eLife   Vol. 10   2021.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:{eLife} Sciences Publications, Ltd  

    DOI: 10.7554/eLife.69340

    Web of Science

    Scopus

    PubMed

    researchmap

  6. Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study

    Shoya Iwanami, Mirjam E. E. Kretzschmar, Keisuke Ejima, Kwang Su Kim, Koji Noshita, Yasuhisa Fujita, Taiga Miyazaki, Shigeru Kohno, Yoshitsugu Miyazaki, Shimpei Morimoto, Shinji Nakaoka, Yoshiki Koizumi, Yusuke Asai, Kazuyuki Aihara, Koichi Watashi, Robin N. Thompson, Kenji Shibuya, Katsuhito Fujiu, Alan S. Perelson, Shingo Iwami, Takaji Wakita

    PLOS Medicine   Vol. 18 ( 7 ) page: e1003660   2021.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1371/journal.pmed.1003660

    Web of Science

    Scopus

    PubMed

    researchmap

  7. Estimation of the incubation period of COVID-19 using viral load data International journal

    Keisuke Ejima, Kwang Su Kim, Christina Ludema, Ana I. Bento, Shoya Iwanami, Yasuhisa Fujita, Hirofumi Ohashi, Yoshiki Koizumi, Koichi Watashi, Kazuyuki Aihara, Hiroshi Nishiura, Shingo Iwami

    Epidemics   Vol. 35   page: 100454 - 100454   2021.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Elsevier {BV}  

    The incubation period, or the time from infection to symptom onset, of COVID-19 has usually been estimated by using data collected through interviews with cases and their contacts. However, this estimation is influenced by uncertainty in the cases' recall of exposure time. We propose a novel method that uses viral load data collected over time since hospitalization, hindcasting the timing of infection with a mathematical model for viral dynamics. As an example, we used reported data on viral load for 30 hospitalized patients from multiple countries (Singapore, China, Germany, and Korea) and estimated the incubation period. The median, 2.5, and 97.5 percentiles of the incubation period were 5.85 days (95 % CI: 5.05, 6.77), 2.65 days (2.04, 3.41), and 12.99 days (9.98, 16.79), respectively, which are comparable to the values estimated in previous studies. Using viral load to estimate the incubation period might be a useful approach, especially when it is impractical to directly observe the infection event.

    DOI: 10.1016/j.epidem.2021.100454

    Web of Science

    Scopus

    PubMed

    researchmap

  8. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro. International journal

    Kaho Shionoya, Masako Yamasaki, Shoya Iwanami, Yusuke Ito, Shuetsu Fukushi, Hirofumi Ohashi, Wakana Saso, Tomohiro Tanaka, Shin Aoki, Kouji Kuramochi, Shingo Iwami, Yoshimasa Takahashi, Tadaki Suzuki, Masamichi Muramatsu, Makoto Takeda, Takaji Wakita, Koichi Watashi

    Frontiers in microbiology   Vol. 12   page: 651403 - 651403   2021.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Coronavirus disease 2019 (COVID-19) has caused serious public health, social, and economic damage worldwide and effective drugs that prevent or cure COVID-19 are urgently needed. Approved drugs including Hydroxychloroquine, Remdesivir or Interferon were reported to inhibit the infection or propagation of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), however, their clinical efficacies have not yet been well demonstrated. To identify drugs with higher antiviral potency, we screened approved anti-parasitic/anti-protozoal drugs and identified an anti-malarial drug, Mefloquine, which showed the highest anti-SARS-CoV-2 activity among the tested compounds. Mefloquine showed higher anti-SARS-CoV-2 activity than Hydroxychloroquine in VeroE6/TMPRSS2 and Calu-3 cells, with IC50 = 1.28 μM, IC90 = 2.31 μM, and IC99 = 4.39 μM in VeroE6/TMPRSS2 cells. Mefloquine inhibited viral entry after viral attachment to the target cell. Combined treatment with Mefloquine and Nelfinavir, a replication inhibitor, showed synergistic antiviral activity. Our mathematical modeling based on the drug concentration in the lung predicted that Mefloquine administration at a standard treatment dosage could decline viral dynamics in patients, reduce cumulative viral load to 7% and shorten the time until virus elimination by 6.1 days. These data cumulatively underscore Mefloquine as an anti-SARS-CoV-2 entry inhibitor.

    DOI: 10.3389/fmicb.2021.651403

    Web of Science

    Scopus

    PubMed

    researchmap

  9. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment International journal

    Hirofumi Ohashi, Koichi Watashi, Wakana Saso, Kaho Shionoya, Shoya Iwanami, Takatsugu Hirokawa, Tsuyoshi Shirai, Shigehiko Kanaya, Yusuke Ito, Kwang Su Kim, Takao Nomura, Tateki Suzuki, Kazane Nishioka, Shuji Ando, Keisuke Ejima, Yoshiki Koizumi, Tomohiro Tanaka, Shin Aoki, Kouji Kuramochi, Tadaki Suzuki, Takao Hashiguchi, Katsumi Maenaka, Tetsuro Matano, Masamichi Muramatsu, Masayuki Saijo, Kazuyuki Aihara, Shingo Iwami, Makoto Takeda, Jane A. McKeating, Takaji Wakita

    iScience   Vol. 24 ( 4 ) page: 102367 - 102367   2021.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Elsevier {BV}  

    Antiviral treatments targeting the coronavirus disease 2019 are urgently required. We screened a panel of already approved drugs in a cell culture model of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and identified two new agents having higher antiviral potentials than the drug candidates such as remdesivir and chroloquine in VeroE6/TMPRSS2 cells: the anti-inflammatory drug cepharanthine and human immunodeficiency virus protease inhibitor nelfinavir. Cepharanthine inhibited SARS-CoV-2 entry through the blocking of viral binding to target cells, while nelfinavir suppressed viral replication partly by protease inhibition. Consistent with their different modes of action, synergistic effect of this combined treatment to limit SARS-CoV-2 proliferation was highlighted. Mathematical modeling in vitro antiviral activity coupled with the calculated total drug concentrations in the lung predicts that nelfinavir will shorten the period until viral clearance by 4.9 days and the combining cepharanthine/nelfinavir enhanced their predicted efficacy. These results warrant further evaluation of the potential anti-SARS-CoV-2 activity of cepharanthine and nelfinavir.

    DOI: 10.1016/j.isci.2021.102367

    Web of Science

    Scopus

    PubMed

    researchmap

  10. Time variation in the probability of failing to detect a case of polymerase chain reaction testing for SARS-CoV-2 as estimated from a viral dynamics model International journal

    Keisuke Ejima, Kwang Su Kim, Shoya Iwanami, Yasuhisa Fujita, Ming Li, Roger S. Zoh, Kazuyuki Aihara, Taiga Miyazaki, Takaji Wakita, Shingo Iwami

    Journal of The Royal Society Interface   Vol. 18 ( 177 ) page: 20200947 - 20200947   2021.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Viral tests including polymerase chain reaction (PCR) tests are recommended to diagnose COVID-19 infection during the acute phase of infection. A test should have high sensitivity; however, the sensitivity of the PCR test is highly influenced by viral load, which changes over time. Because it is difficult to collect data before the onset of symptoms, the current literature on the sensitivity of the PCR test before symptom onset is limited. In this study, we used a viral dynamics model to track the probability of failing to detect a case of PCR testing over time, including the presymptomatic period. The model was parametrized by using longitudinal viral load data collected from 30 hospitalized patients. The probability of failing to detect a case decreased toward symptom onset, and the lowest probability was observed 2 days after symptom onset and increased afterwards. The probability on the day of symptom onset was 1.0% (95% CI: 0.5 to 1.9) and that 2 days before symptom onset was 60.2% (95% CI: 57.1 to 63.2). Our study suggests that the diagnosis of COVID-19 by PCR testing should be done carefully, especially when the test is performed before or way after symptom onset. Further study is needed of patient groups with potentially different viral dynamics, such as asymptomatic cases.

    DOI: 10.1098/rsif.2020.0947

    Web of Science

    Scopus

    PubMed

    researchmap

  11. A quantitative model used to compare withinhost SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2

    Kim K.S., Ejima K., Iwanami S., Fujita Y., Ohashi H., Koizumi Y., Asai Y., Nakaoka S., Watashi K., Aihara K., Thompson R.N., Ke R., Perelson A.S., Iwami S.

    PLoS Biology   Vol. 19 ( 3 )   2021.3

     More details

    Language:Japanese   Publisher:PLoS Biology  

    The scientific community is focused on developing antiviral therapies to mitigate the impacts of the ongoing novel coronavirus disease 2019 (COVID-19) outbreak. This will be facilitated by improved understanding of viral dynamics within infected hosts. Here, using a mathematical model in combination with published viral load data, we compare within-host viral dynamics of SARS-CoV-2 with analogous dynamics of MERS-CoV and SARS-CoV. Our quantitative analyses using a mathematical model revealed that the within-host reproduction number at symptom onset of SARS-CoV-2 was statistically significantly larger than that of MERS-CoV and similar to that of SARS-CoV. In addition, the time from symptom onset to the viral load peak for SARS-CoV-2 infection was shorter than those of MERS-CoV and SARS-CoV. These findings suggest the difficulty of controlling SARS-CoV-2 infection by antivirals. We further used the viral dynamics model to predict the efficacy of potential antiviral drugs that have different modes of action. The efficacy was measured by the reduction in the viral load area under the curve (AUC). Our results indicate that therapies that block de novo infection or virus production are likely to be effective if and only if initiated before the viral load peak (which appears 2-3 days after symptom onset), but therapies that promote cytotoxicity of infected cells are likely to have effects with less sensitivity to the timing of treatment initiation. Furthermore, combining a therapy that promotes cytotoxicity and one that blocks de novo infection or virus production synergistically reduces the AUC with early treatment. Our unique modeling approach provides insights into the pathogenesis of SARSCoV- 2 and may be useful for development of antiviral therapies.

    DOI: 10.2110/JSR.2020.113

    Scopus

  12. Should a viral genome stay in the host cell or leave? A quantitative dynamics study of how hepatitis C virus deals with this dilemma Reviewed

    Iwanami, S., Kitagawa, K., Ohashi, H., Asai, Y., Shionoya, K., Saso, W., Nishioka, K., Inaba, H., Nakaoka, S., Wakita, T., Diekmann, O., Iwami, S., Watashi, K.

    PLoS Biology   Vol. 18 ( 7 ) page: e3000562   2020.7

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Public Library of Science ({PLoS})  

    DOI: 10.1371/journal.pbio.3000562

    Web of Science

    Scopus

    PubMed

    researchmap

  13. Revealing uninfected and infected target cell dynamics from peripheral blood data in highly and less pathogenic simian/human immunodeficiency virus infected Rhesus macaque Reviewed

    Hara, A., Iwanami, S., Ito, Y., Miura, T., Nakaoka, S., Iwami, S.

    Journal of Theoretical Biology   Vol. 479   page: 29 - 36   2019.10

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jtbi.2019.07.005

    Web of Science

    Scopus

    PubMed

    researchmap

  14. 骨髄球バイパスを含む造血システムの数理モデルを用いた1細胞移植実験のデータ解析 (第14回生物数学の理論とその応用 : 構造化個体群ダイナミクスとその応用)

    岩波 翔也, 山本 玲, 岩見 真吾, 波江野 洋

    数理解析研究所講究録   Vol. 2087 ( 2087 ) page: 77 - 85   2018.8

     More details

    Language:Japanese   Publisher:京都大学数理解析研究所  

    CiNii Research

  15. Quantitative immunology by data analysis using mathematical models

    Iwanami S.

    Encyclopedia of Bioinformatics and Computational Biology: ABC of Bioinformatics   Vol. 1-3   page: 984 - 992   2018.1

     More details

    Publisher:Encyclopedia of Bioinformatics and Computational Biology: ABC of Bioinformatics  

    DOI: 10.1016/B978-0-12-809633-8.20250-1

    Scopus

  16. 骨髄球バイパスを含む造血システムの数理モデル (第13回生物数学の理論とその応用 : 連続および離散モデルのモデリングと解析)

    岩波 翔也, 山本 玲, 岩見 真吾, 波江野 洋

    数理解析研究所講究録   Vol. 2043 ( 2043 ) page: 102 - 108   2017.9

     More details

    Language:Japanese   Publisher:京都大学数理解析研究所  

    CiNii Research

  17. A highly pathogenic simian/human immunodeficiency virus effectively produces infectious virions compared with a less pathogenic virus in cell culture Reviewed

    Iwanami, S., Kakizoe, Y., Morita, S., Miura, T., Nakaoka, S., Iwami, S.

    Theoretical Biology and Medical Modelling   Vol. 14 ( 1 ) page: 9   2017.4

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/s12976-017-0055-8

    Web of Science

    Scopus

    PubMed

    researchmap

▼display all

Books 1

  1. Quantitative immunology by data analysis using mathematical models

    Iwanami, S., Iwami, S.

    2018.1  ( ISBN:9780128114148

     More details

KAKENHI (Grants-in-Aid for Scientific Research) 1

  1. 組織維持を担う細胞群個体群動態の理解と定量的データ解析

    Grant number:19J12319  2019.4 - 2021.3

    日本学術振興会  科学研究費助成事業 特別研究員奨励費  特別研究員奨励費

    岩波 翔也, 岩波 翔也

      More details

    Authorship:Other 

    生体内では、細胞群が相互に影響を与え合いながら組織の恒常性を維持している。ここでは、幹細胞が維持する組織として老化の研究が盛んに行われている造血組織と、細胞が組織を形成と破壊のバランスを取りながら維持している骨組織に着目した。
    造血幹細胞は全ての血液細胞と免疫細胞に分化する能力を持ち、生涯にわたって造血組織を維持すると考えられている。また、造血幹細胞の分化機構について、様々な研究結果から複数のモデルが提唱されている。さらに、加齢による造血幹細胞の能力の変化が、造血組織の老化を引き起こすという研究成果が報告されている。造血幹細胞が造血組織を維持し、老化するメカニズムを解明するために、造血幹細胞分化を記述する数理モデルを開発した。この数理モデルを用いて、若齢マウスと老齢マウスから取得された造血幹細胞を移植したときの末梢血中での各細胞系統の変動を解析した。このとき、非線形混合効果モデルの手法を取り入れ、マウスでの移植実験のデータのばらつきを統計的に扱うことが可能な解析手法を構築した。若齢マウスと老齢マウスの造血幹細胞の能力を比較し、老化に伴って骨髄球の産生が多くなることを説明した。今後は、造血幹細胞分化の確率シミュレータを開発し、細胞の分化と組織の維持の関係性の定性的・定量的な解釈を目指す。
    骨組織は骨芽細胞と破骨細胞が相互に作用し合うことで、骨形成と骨吸収のバランスをとりながら維持され、一般に、加齢と共に骨量が減少する。また、重力変化や閉経などの摂動によって骨量が変化することが示唆されている。ここでは、マウスで取得された骨代謝マーカーと骨量変動の長期の時系列データと、人工的に重力をかけられたマウスのデータを同時に解析し、骨代謝マーカーの変動から骨量の変動を説明することに成功した。今後は、他の摂動実験を説明しうる数理モデルを開発していく。

    researchmap